Hyaluronan Mediated Motility Receptor (HMMR) Antibody (FITC)

Background

The hyaluronan-mediated motility receptor (HMMR), also known as RHAMM (Receptor for Hyaluronan-Mediated Motility), is a protein encoded by the HMMR gene in humans. Originally identified in studies focusing on cancer cell motility, HMMR functions as a receptor for hyaluronan (HA), a component of the extracellular matrix (ECM) involved in tissue hydration, structural integrity, and cellular communication. HMMR has attracted significant scientific interest due to its roles in cellular adhesion, proliferation, migration, and wound healing. Its expression is often upregulated in cancer cells, contributing to increased cell motility and invasiveness, making it a focal point in oncology research. HMMR functions not only as a surface receptor but also intracellularly, interacting with various signaling pathways and microtubule networks, which influences cell division and chromosomal stability. Given its involvement in pathways like RAS and ERK and its interaction with the mitotic spindle, HMMR is critical in cell cycle regulation and tissue morphogenesis. Dysregulated HMMR expression has been associated with cancer progression, inflammatory diseases, and even osteoarthritis, placing it at the intersection of various physiological and pathological processes.